Case series:CD19 Allo-CAR-T

A single-center, single-arm, open-label, dose escalation study to evaluate the safety & preliminary anti-tumor activity of CD19 allogeneic chimeric antigen receptor T cells (CD19 Allo-CAR-T) for the treatment of patients with relapsed / refractory B cell malignancies

A single-center, single-arm, open-label, dose escalation study for evaluating the safety & preliminary anti-tumor activity of CD19 allogeneic chimeric antigen receptor T cells (CD19 Allo-CAR-T) in the treatment of patients with relapsed / refractory B cell malignancies